1-氟-2,5-二甲基-4-硝基苯 | 1736-88-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-氟-2,5-二甲基-4-硝基苯
• 英文名称: 1-Fluor-4-nitro-2,5-dimethyl-benzol
• 英文别名: 2-Nitro-5-fluor-p-xylol；1-fluoro-2,5-dimethyl-4-nitrobenzene
• CAS: 1736-88-5
• 化学式: C₈H₈FNO₂
• 分子量: 169.155
• InChiKey: VUOPPDPBZDVFHW-UHFFFAOYSA-N

物化性质

• 熔点：
  49-50 °C
• 沸点：
  107.0-107.5 °C(Press: 14 Torr)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P310,P330,P361,P403+P233,P405,P501
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H311,H331
• 包装等级：
  III

反应信息

• 作为反应物：
  描述：

  1-氟-2,5-二甲基-4-硝基苯 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 tin(ll) chloride 作用下， 生成 2,5-Bis(brom-methyl)-1,4-difluorbenzol
  参考文献：
  名称：

  二氟四氰基喹二甲烷：四硫富瓦烯盐中“金属”行为的电子亲和力截止

  摘要：

  描述了2,5-二氟四氰基喹二甲烷及其四硫富瓦烯盐的合成和性质，其电导率受受体电子亲和力增强的限制。

  DOI：

  10.1039/c39790001027
• 作为产物：
  描述：

  2-氟对二甲苯 在 硝酸 作用下， 生成 1-氟-2,5-二甲基-4-硝基苯
  参考文献：
  名称：

  二氟四氰基喹二甲烷：四硫富瓦烯盐中“金属”行为的电子亲和力截止

  摘要：

  描述了2,5-二氟四氰基喹二甲烷及其四硫富瓦烯盐的合成和性质，其电导率受受体电子亲和力增强的限制。

  DOI：

  10.1039/c39790001027

文献信息

• CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION
  申请人：Fresenius Kabi Deutschland GmbH

  公开号：US20150297738A1

  公开（公告）日：2015-10-22

  The present invention relates to a hydroxyalkyl starch conjugate and a method for preparing the same, said hydroxyalkyl starch conjugate comprising a hydroxyalkyl starch derivative and a cytotoxic agent, the cytotoxic agent comprising at least one secondary hydroxyl group, wherein the hydroxyalkyl starch is linked via said secondary hydroxyl group to the cytotoxic agent. The conjugate according to the present invention has a structure according to the following formula HAS′(-L-M) n wherein M is a residue of the cytotoxic agent, L is a linking moiety, HAS′ is the residue of the hydroxyalkyl starch derivative, and n is greater than or equal to 1, and wherein the hydroxyalkyl starch derivative has a mean molecular weight (MW) above the renal threshold.

  本发明涉及一种羟烷基淀粉共轭物及其制备方法，所述羟烷基淀粉共轭物包括羟烷基淀粉衍生物和细胞毒性药剂，所述细胞毒性药剂包括至少一个次级羟基，其中羟烷基淀粉通过所述次级羟基与细胞毒性药剂连接。根据本发明的共轭物具有以下公式HAS'(-L-M)n的结构，其中M是细胞毒性药剂的残基，L是连接基团，HAS'是羟烷基淀粉衍生物的残基，n大于或等于1，且羟烷基淀粉衍生物的平均分子量（MW）高于肾脏阈值。
• [EN] SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PRMT5
  申请人：LUPIN LTD

  公开号：WO2019116302A1

  公开（公告）日：2019-06-20

  The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.

  这项发明涉及公式（I）的取代双环杂环化合物，其药学上可接受的盐以及用于治疗与PRMT5 5酶过度表达相关的疾病、紊乱或状况的药物组合物。该发明还涉及治疗与PRMT5酶过度表达相关的疾病、紊乱或状况的方法。
• SUBSTITUTED OXAZOLIDINONES AND THEIR USE
  申请人：Allerheiligen Swen

  公开号：US20100261759A1

  公开（公告）日：2010-10-14

  The invention relates to novel substituted oxazolidinones, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

  这项发明涉及新型取代氧唑烷酮，其制备方法，其用于治疗和/或预防疾病以及用于制备用于治疗和/或预防疾病，特别是血栓栓塞性疾病的药物。
• Conjugates of a Polymer and a Protein Linked by an Oxime Group
  申请人：Sommermeyer Klaus

  公开号：US20080206182A1

  公开（公告）日：2008-08-28

  The present invention relates to polymers functionalized by an aminooxy group or a derivative thereof, conjugates, wherein the functionalized polymers are covalently coupled with a protein by an oxime linking group, a process for preparing the functionalized polymers, a process for preparing the conjugates, functionalize polymers as obtainable by the process of the present invention, conjugates as obtainable by the process of the present invention, and pharmaceutical compositions comprising at least one conjugate of the present invention and the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.

  本发明涉及通过氨氧基团或其衍生物功能化的聚合物，共轭物，其中所述功能化的聚合物通过肟键连接基团与蛋白质共价耦合，制备所述功能化聚合物的方法，制备所述共轭物的方法，通过本发明方法获得的功能化聚合物，通过本发明方法获得的共轭物，以及包含本发明至少一种共轭物的制药组合物，以及所述共轭物和组合物在预防或治疗人体或动物体中的使用。
• Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation
  申请人：Zander Nobert

  公开号：US20120046235A9

  公开（公告）日：2012-02-23

  Conjugates of an active substance and hydroxyalkyl starch (HAS) are provided herein. The active substance and the HAS are linked by a chemical moiety having a structure according to formula (I) wherein Y is O or S, and X is SH or (F). The conjugate has a structure according to formula (IV) wherein HAS′ is a residue of HAS or a derivative thereof linked to the thioester group, and AS′ is a residue of the active substance or derivative thereof linked to the alpha-X beta-amino group; or a structure according to formula (V) wherein HAS′ is a residue of HAS or derivative thereof linked to the alpha-X beta-amino group, and AS′ is a residue of the active substance or derivative thereof linked to the thioester group, and wherein the group —(C═Y) is derived from the thioester group —(C═Y)—S—R′ and the group HN—CH—CH 2 —X is derived from the alpha-X beta amino group.

  本文提供了一种活性物质和羟基烷基淀粉（HAS）的共轭物。活性物质和HAS通过具有公式（I）结构的化学基团连接，其中Y为O或S，X为SH或（F）。共轭物具有公式（IV）结构，其中HAS'是HAS的残基或其衍生物，连接到硫酸酯基团，AS'是活性物质或其衍生物的残基，连接到α-Xβ-氨基基团；或具有公式（V）结构，其中HAS'是HAS或其衍生物的残基，连接到α-Xβ-氨基基团，AS'是活性物质或其衍生物的残基，连接到硫酸酯基团，其中—（C = Y）基团来自硫酸酯基团—（C = Y）—S—R'，而HN—CH—CH2—X基团来自α-Xβ-氨基基团。